Outcome of the Board Meeting - Financial Results, Re-Appointment of Internal Auditor and Cost Auditor, Reconstitute of Risk Management Committee
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Drugs Ltd reported strong audited results for FY26. Consolidated revenue from operations grew to ₹2,38,703 lakhs (approximately ₹2,387 crore), up from ₹1,43,384 lakhs in FY25, representing revenue growth of about 66.5%. Profit after tax on consolidated basis surged to ₹21,090 lakhs compared to ₹4,055 lakhs in the previous year — a growth of over 420%. The company declared an un-modified audit opinion for both standalone and consolidated financial statements. Additionally, the board re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY27 and M/s Raman S. Shah & Co. as Internal Auditor for 3 years. The Risk Management Committee was reconstituted with inclusion of Narendra J. Salvi as a member. Company operates only in the pharmaceuticals segment and has 3 subsidiaries with 2 step-down subsidiaries.
The company delivered exceptional financial performance with consolidated PAT growing over 5x year-on-year, indicating strong operational momentum and likely margin improvement. Clean audit opinion with no modifications supports financial reliability. Shareholders can view this positively given the substantial profit growth.